SG Americas Securities LLC Decreases Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

SG Americas Securities LLC reduced its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 85.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 6,554 shares of the biotechnology company’s stock after selling 37,638 shares during the period. SG Americas Securities LLC’s holdings in ADMA Biologics were worth $112,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ADMA. State Street Corp boosted its position in shares of ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Perpetual Ltd purchased a new stake in ADMA Biologics in the fourth quarter valued at about $62,300,000. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the third quarter valued at about $61,858,000. Principal Financial Group Inc. boosted its holdings in ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after acquiring an additional 1,059,394 shares in the last quarter. Finally, First Turn Management LLC purchased a new stake in shares of ADMA Biologics during the third quarter worth about $13,293,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 0.3 %

ADMA Biologics stock opened at $15.84 on Thursday. The business’s 50-day simple moving average is $17.50 and its two-hundred day simple moving average is $17.77. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market cap of $3.74 billion, a PE ratio of 56.57 and a beta of 0.75. ADMA Biologics, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $23.64.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on ADMA shares. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright upped their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.